Highest-materiality recent filing
Emmaus Q1 revenue down 18% to $2.0M; net loss widens to $3.3M
Net revenues $2.0M vs $2.4M YoY; U.S. sales fell 33% on generic L-Glutamine competition.
Emmaus 2025 net revenue $12.5M (-25% YoY); net loss widens to $7.2M
Net revenue $12.5M vs $16.7M in 2024; net loss $7.2M ($0.11/sh) vs $6.5M ($0.10/sh).
Emmaus Life Sciences licenses Endari to NeoImmuneTech for US/Canada with upfront and royalties
Emmaus grants NeoImmuneTech (NIT) exclusive rights to market Endari for sickle cell disease in US and Canada; upfront payment plus royalty on NIT sales.
Emmaus Life Sciences exchanges $3M note for $600K note and 6.33M shares (9% dilution)
Exchanged $3M convertible note (10% interest, conversion $0.13) for $600K new note (10%, conversion $0.01 adjustable) and 6,332,692 shares valued at ~$0.38 each.
Emmaus Q3 net loss $2.1M; revenue down 38% YoY to $3.4M on generic competition
Net loss of $2.1M ($0.03/share) vs net income of $1.8M in Q3 2024.
Emmaus Life Sciences Q2 net revenue down 48% to $2.8M; net loss narrows to $1.1M
Net revenue $2.8M, down 48% YoY from $5.4M; competition from generic L-Glutamine cited.
Emmaus Life Sciences reports 2024 net revenue down 44% to $16.7M; net loss widens to $0.10/share
Net revenue $16.7M in 2024, down 44% from $29.6M in 2023 due to inventory shortage.
Emmaus Life Sciences Q3 net revenue up 9% to $5.5M; net income $1.8M vs $0.07M YoY
Net revenues $5.5M (+9% YoY) driven by Middle East sales; U.S. sales fell due to generic L-Glutamine competition.
Revenue falls 55% to $7.9M, net loss $6.5M; auditor Baker Tilly declines reappointment
Net revenue for H1 2024 was $7.9M, down 55% from $17.5M in H1 2023, due to inventory shortages.
Emmaus 2023 revenue up 61% to $29.6M, net loss narrows to $3.7M
Net revenue $29.6M (vs $18.4M in 2022); operating income $3.5M vs loss $6.6M.
Exchanged $9M principal of 2% convertible notes due Feb 24, 2024 for new 10% notes due Feb 24, 2025.
Emmaus exchanges $2.2M in director-held notes for 8.2M shares at $0.29/share
Exchanged $1M note from Zen for 3,760,983 shares and $1.2M note from Lim for 4,447,426 shares.
Emmaus Life Sciences Q3 2023 net income $0.1M vs loss of $0.4M year ago
Q3 net revenues $5.0M, up from $4.9M in Q3 2022; nine-month revenues $22.5M vs $12.5M.
Emmaus CEO and Chairman steps down; interim Co-Presidents appointed
Yutaka Niihara, M.D., Ph.D., leaves CEO and Chairman roles effective Aug 18, 2023, to pursue other projects; remains a director.
Emmaus Life Sciences reports record Q2 net revenue of $10.8M; posts $3.3M income from operations
Q2 net revenue $10.8M (up 151% YoY); six-month net revenue $17.5M (up 133% YoY).
Emmaus Life Sciences Q1 net loss $3.5M, revenue up 109% to $6.8M, cash dwindles
Net revenues $6.8M, up 109% YoY from $3.2M, driven by U.S. and MENA sales.
Emmaus Life Sciences reports FY2022 net loss of $10.6M; going concern doubt raised
Net revenues $18.4M, down 10.7% from $20.6M in 2021; operating loss widened to $6.6M from $6.1M.
Emmaus Life Sciences grants CEO Yutaka Niihara warrant to purchase 7.5M shares at $4.50
CEO Niihara receives 5-year warrant for 7.5M shares at $4.50, fully vested on grant date.
Emmaus Q3 net loss narrows to $0.4M; revenue slides YoY; working capital insufficient
Q3 net revenues $4.9M, up 15% from Q2 but down YoY from $5.8M; nine-month revenues $12.5M vs $17.6M.
Net revenues Q2 2022 $4.3M, down 34% YoY from $6.5M; sequentially up 33% from Q1 2022 $3.2M.
Three Emmaus directors resign after dispute with CEO over financial oversight and cost cuts
Lori Teranishi, Alfred Lui, and Jane Pine Wood resigned June 8, 2022, at CEO Yutaka Niihara's request.
Emmaus Q1 revenue drops 40% to $3.2M; cash falls to $0.8M; working capital insufficient
Net revenue $3.2M, down from $5.3M YoY; sell-through improved but overstocking by distributors hit revenue.
Emmaus Life Sciences FY2021 revenue $20.6M; net loss $15.9M vs prior-year net income
Net revenue $20.6M, down 11% from $23.2M in 2020; sales volume steady but discounts hurt.
Emmaus restates 2020 financials; net income rises to $1.4M from $1.1M
Non-reliance on FY2020 financials due to equity method investment misstatement; restated 10-K/A filed with unqualified audit opinion.
On November 4, 2024, Seah Lim, M.D., Ph.D., resigned as a director of Emmaus Life Sciences, Inc. (“we,” “us,” “our,” “Emmaus” or the “company”) for personal reasons and expressed his best wishes to the company.
the Board appointed Jon Kuwahara to fill the resulting vacancy on the Board of Directors. The Board also appointed Mr. Kuwahara to serve as the Chair of the two-person Audit Committee.
On September 30, 2024, George Sekulich resigned as a member of the Board of Directors
in connection with the termination of his employment as our Chief Commercial Officer on October 4, 2024
On July 15, 2024, the Board of Directors of Emmaus Life Sciences, Inc. (“we,” “us,” “our,” “Emmaus” or the “company”) appointed Willis Lee as our Chief Executive Officer and eliminated the former offices of interim Co-President.
Also on October 2, 2023, the Board of Directors appointed Willis Lee, the Co-President and Chief Operating Officer, to serve as Chairman of the Board of Directors.
Yutaka Niihara, M.D., M.P.H., the former Chairman and Chief Executive Officer, resigned as a director effective September 25, 2023.
Willis Lee and George Sekulich have been appointed as interim Co-Presidents of Emmaus.
Willis Lee and George Sekulich have been appointed as interim Co-Presidents of Emmaus.
the Board appointed Ian Zwicker as a director of the company and as the Chair and sole member of the Audit Committee
The Board also appointed Seah H. Lim, M.D., Ph.D. as a director to fill a vacancy on the five-person Board.
On September 28, 2022, Dr. Masaharu Osato resigned as a member of the Board of Directors of Emmaus Life Sciences, Inc.
Max materiality 0.85 · Median 0.60 · Most common event earnings